Pre-Study protocol MagPEP: A multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Fluhr, Gabriele ^a   Mayerle, Julia ^a   Weber, Eckhard ^a   Aghdassi, Ali ^a   Simon, Peter ^a   Gress, Thomas ^b   Seufferlein, Thomas ^c   Mössner, Joachim ^d   Stallmach, Andreas ^e   Rösch, Thomas ^f   Müller, Martina ^g   Siegmund, Britta ^h   Büchner Steudel, Petra ⁱ   Zuber Jerger, Ina ^g   Kantowski, Marcus ^e   Hoffmeister, Albrecht ^d   Rosendahl, Jonas ^d   Linhart, Thomas ^b   Maul, Jochen ^h   Czakó, László ^j   Hegyi, Péter ^j   Kraft, Matthias ^a   Engel, Georg ^a   Kohlmann, Thomas ^a   Glitsch, Anne ^a   Pickartz, Tilman ^a   Budde, Christoph ^a   Nitsche, Claudia ^a   Storck, Kirsten ^a   Lerch, Markus M ^a   more..

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^j UNIVERSITY OF SZEGED   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; MAGNESIUM SULFATE; PLACEBO; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAIN; PANCREATITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; CALCIUM SIGNALING; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; INTRAVENOUS ADMINISTRATION; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; ADMINISTRATION, INTRAVENOUS; ADULT; CALCIUM SIGNALING; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; HUMANS; INCIDENCE; MAGNESIUM SULFATE; PANCREATITIS; SEVERITY OF ILLNESS INDEX;

EID: 84872138865     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-11     Document Type: Article

References (24)

1. Freeman ML, Guda NM: Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004, 59:845-864
2. Freeman ML, Disario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al: Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001, 54:425-434
3. Zheng M, Chen Y, Yang X, Li J, Zhang Y, Zeng Q: Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2007, 7:6
4. Rudin D, Kiss A, Wetz RV, Sottile VM: Somatostatin and gabexate for postendoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 2007, 22:977-983
5. Andriulli A, Caruso N, Quitadamo M, Forlano R, Leandro G, Spirito F, et al: Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. 7. JOP 2003, 4:41-48
6. Bai Y, Gao J, Zou DW, Li ZS: Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas 2008, 37:241-246
7. Katsinelos P, Fasoulas K, Paroutoglou G, Chatzimavroudis G, Beltsis A, Terzoudis S, et al: Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy 2012, 44(1):53-9
8. Omata F, Deshpande G, Tokuda Y, Takahashi O, Ohde S, Carr-Locke DL, et al: Meta-analysis: somatostatin or its long-acting analogue, ocreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol 2010, 45:885-95
9. Bai Y, Gao J, Zhang W, Zou D, Li Z: Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008, 28:557-564
10. Zheng M, Chen Y, Bai J, Xin Y, Pan X, Zhao L: Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2008, 37:247-253
11. Zheng M, Bai J, Yuan B, Lin F, You J, Lu M, et al: Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol 2008, 8:6
12. Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD: A metaanalysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008, 57:1262-1267
13. Barkay O, Niv E, Santo E, Bruck R, Hallak A, KonikoffFM: Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebocontrolled trial. Surg Endosc 2008, 22:1971-1976
14. Sherman S, Cheng CL, Costamagna G, Binmoeller KF, Puespoek A, Aithal GP, et al: Efficacy of Recombinant Human Interleukin-10 in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in Subjects With Increased Risk. Pancreas 2009, 38:267-274
15. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al: A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012, 366:1414-22
16. Weiss FU, Halangk W, Lerch MM: New advances in pancreatic cell physiology and pathophysiology. Best Pract Res Clin Gastroenterol 2008, 22:3-15
17. Kruger B, Albrecht E, Lerch MM: The role of intracellular calcium signaling in premature protease activation and the onset of pancreatitis. Am J Pathol 2000, 157:43-50
18. Mooren FC, Hlouschek V, Finkes T, Turi S, Weber IA, Singh J, et al: Early changes in pancreatic acinar cell calcium signaling after pancreatic duct obstruction. J Biol Chem 2003, 278:9361-9369
19. Venglovecz V, Rakonczay Z Jr, Ozsvári B, Takács T, Lonovics J, Varró A, et al: Effects of bile acids on pancreatic ductal bicarbonate secretion in guinea pig. Gut 2008, 57:1102-12
20. Venglovecz V, Hegyi P, Rakonczay Z Jr, Tiszlavicz L, Nardi A, Grunnet M, et al: Pathophysiological relevance of apical large-conductance Ca2 +-activated potassium channels in pancreatic duct epithelial cells. Gut 2011, 60:361-9
21. Mooren FC, Turi S, Gunzel D, Schlue WR, Domschke W, Singh J, et al: Calcium-magnesium interactions in pancreatic acinar cells. FASEB J 2001, 15:659-672
22. Turi S, Hlouschek V, Mooren FC, Schnekenburger J, Domschke W, Lerch MM: Effects of prophylactic magnesium treatment on the onset and course of acute experimental pancreatitis. Gastroenterology 2000, 118:A430
23. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al: Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991, 37:383-393
24. Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E: Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol 2008, 69:33-39